0
0
0
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
6/14/2024, 8:05 AM
Summary of Bill HJRES 145
Bill 118 hjres 145 is a piece of legislation that aims to disapprove of a rule submitted by the Food and Drug Administration (FDA) regarding "Medical Devices; Laboratory Developed Tests." The rule in question falls under chapter 8 of title 5, United States Code, which governs the regulatory process for federal agencies.
The bill seeks to exercise congressional oversight by disapproving of the FDA's rule, which likely means that Congress believes the rule is not in the best interest of the public or is not in line with congressional intent. The rule in question likely pertains to the regulation of laboratory developed tests, which are medical tests developed and performed within a single laboratory.
If this bill is passed, it would prevent the FDA from implementing the rule and would send a message that Congress does not support the FDA's approach to regulating laboratory developed tests. This could have significant implications for the FDA's ability to regulate medical devices and tests in the future. Overall, Bill 118 hjres 145 represents a significant moment in the ongoing debate over the regulation of medical devices and tests in the United States. It highlights the tension between congressional oversight and agency authority, and could have far-reaching implications for the FDA's regulatory powers.
The bill seeks to exercise congressional oversight by disapproving of the FDA's rule, which likely means that Congress believes the rule is not in the best interest of the public or is not in line with congressional intent. The rule in question likely pertains to the regulation of laboratory developed tests, which are medical tests developed and performed within a single laboratory.
If this bill is passed, it would prevent the FDA from implementing the rule and would send a message that Congress does not support the FDA's approach to regulating laboratory developed tests. This could have significant implications for the FDA's ability to regulate medical devices and tests in the future. Overall, Bill 118 hjres 145 represents a significant moment in the ongoing debate over the regulation of medical devices and tests in the United States. It highlights the tension between congressional oversight and agency authority, and could have far-reaching implications for the FDA's regulatory powers.
Read the Full Bill
Current Status of Bill HJRES 145
Bill HJRES 145 is currently in the status of Bill Introduced since May 16, 2024. Bill HJRES 145 was introduced during Congress 118 and was introduced to the House on May 16, 2024. Bill HJRES 145's most recent activity was Referred to the House Committee on Energy and Commerce. as of May 16, 2024
Bipartisan Support of Bill HJRES 145
Total Number of Sponsors
1Democrat Sponsors
0Republican Sponsors
1Unaffiliated Sponsors
0Total Number of Cosponsors
8Democrat Cosponsors
0Republican Cosponsors
8Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HJRES 145
Primary Policy Focus
HealthAlternate Title(s) of Bill HJRES 145
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Comments
Sponsors and Cosponsors of HJRES 145
Latest Bills
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Bill HR 8469May 16, 2026
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Bill HR 8845May 16, 2026
LIFT Act
Bill HR 8864May 16, 2026
Creating Early Childhood Leaders Act
Bill HR 8859May 16, 2026
To amend title 5, United States Code, to add certain employees of the Bureau of Alcohol, Tobacco, Firearms and Explosives to the definition of employees in fire protection activities for the purpose of compensation for certain illnesses and diseases deemed to be proximately caused by employment in fire protection activities.
Bill HR 8863May 16, 2026
Expressing support for the designation of May 17, 2026, as "DIPG Awareness Day" to raise awareness and encourage research into cures for diffuse intrinsic pontine glioma (DIPG) and pediatric cancers in general.
Bill HRES 1295May 16, 2026
To amend title 18, United States, to include property damage in acts that constitute domestic terrorism, and for other purposes.
Bill HR 8843May 16, 2026
CRUISE Act
Bill HR 7083May 16, 2026
To allow Americans to sue federal officials for constitutional violations of voting rights and election law.
Bill HR 8858May 16, 2026
Supporting the goals and ideals of "National Charter Schools Week", to be observed from May 10 through May 16, 2026.
Bill HRES 1298May 16, 2026
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests".
Bill SJRES 82June 12, 2024




